Document Detail


Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis.
MedLine Citation:
PMID:  21608334     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Increased cardiovascular morbidity has become a leading cause of mortality in rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNFa) inhibitors may influence flow-mediated vasodilation (FMD) of the brachial artery, common carotid intima-media thickness (ccIMT) and arterial stiffness indicated by pulse-wave velocity (PWV) in RA.
OBJECTIVES: To assess the effects of adalimumab treatment on FMD, ccIMT and PWV in early RA.
METHODS: Eight RA patients with a disease duration < or =1 year received 40 mg adalimumab subcutaneously every 2 weeks. Ultrasound was used to assess brachial FMD and ccIMT. PWV was determined by arteriograph. These parameters were correlated with C-reactive protein, vonWillebrand factor (vWF), immunoglobulin M (IgM)-rheumatoid factor (RF), anti-CCP levels and 28-joint disease activity score (DAS28).
RESULTS: Adalimumab therapy successfully ameliorated arthritis as it decreased CRP levels (P = 0.04) and DAS28 (P < 0.0001). Endothelial function (FMD) improved in comparison to baseline (P < 0.05). ccIMT decreased after 24 weeks, indicating a mean 11.9% significant improvement (P = 0.002). Adalimumab relieved arterial stiffness (PWV) after 24 weeks. Although plasma vWF levels decreased only non-significantly after 12 weeks of treatment, an inverse correlation was found between FMD and vWF (R = -0.643, P = 0.007). FMD also inversely correlated with CRP (R = -0.596, P= 0.015). CRP and vWF also correlated with each other (R = 0.598, P = 0.014). PWV and ccIMT showed a positive correlation (R = 0.735, P = 0.038).
CONCLUSIONS: Treatment with adalimumab exerted favorable effects on disease activity and endothelial dysfunction. It also ameliorated carotid atherosclerosis and arterial stiffness in patients with early RA. Early adalimumab therapy may have an important role in the prevention and management of vascular comorbidity in RA.
Authors:
György Kerekes; Pál Soltész; Gabriella Szucs; Szilvia Szamosi; Henriett Dér; Zoltán Szabó; László Csáthy; Andrea Váncsa; Peter Szodoray; Gyula Szegedi; Zoltán Szekanecz
Related Documents :
3277334 - New developments in the pathogenesis of smoke inhalation-induced pulmonary edema.
25173354 - Left carotid-anterior cerebral artery anastomosis diagnosed by mr angiography: a case r...
21646234 - Treatment of pulmonary embolism using ultrasound-accelerated thrombolysis directly into...
7416604 - Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoki...
17317384 - Turner's syndrome and coronary artery disease.
7978514 - Percutaneous transluminal coronary angioplasty of "superdominant" left anterior descend...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Israel Medical Association journal : IMAJ     Volume:  13     ISSN:  1565-1088     ISO Abbreviation:  Isr. Med. Assoc. J.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-05-25     Completed Date:  2011-06-14     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  100930740     Medline TA:  Isr Med Assoc J     Country:  Israel    
Other Details:
Languages:  eng     Pagination:  147-52     Citation Subset:  IM    
Affiliation:
Cardiovascular Unit, Third Department of Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / complications*
Atherosclerosis / physiopathology,  prevention & control*
Brachial Artery / physiopathology,  ultrasonography
Carotid Artery, Common / physiopathology,  ultrasonography
Elasticity
Endothelium, Vascular / drug effects
Female
Humans
Male
Middle Aged
Vascular Diseases / etiology,  prevention & control*
Vasodilation / drug effects*
von Willebrand Factor / analysis
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/von Willebrand Factor; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
Next Document:  Impact of dialysis type on outcome of acute renal failure in children: a single-center experience.